Literature DB >> 1524517

Cerebral glucose utilization in motor neuron disease.

J M Hoffman1, J C Mazziotta, T C Hawk, R Sumida.   

Abstract

Positron emission tomography with fluorodeoxyglucose F 18 (18F-fluorodeoxyglucose) was used to examine regional cerebral glucose metabolism in individuals with motor neuron disease. Motor neuron disease involves selective loss of motor neurons, large pyramidal cells in the motor cortex, and corticospinal tract degeneration. We postulated that the local cerebral metabolic rate of glucose should correlate with this regional neuronal cell loss. Glucose metabolism values in patients with motor neuron disease were reduced compared with those of controls in several regions; however, when corrected for multiple comparisons, no significant difference was observed between patients with motor neuron disease and age-matched controls. No correlation was noted between the local cerebral metabolic rate of glucose and duration or severity of illness. Correlation between metabolic changes with objective findings on neurologic examination, including motor weakness and tendon reflexes, provided interesting results, including a decline in glucose metabolism with progressive weakness and upper motor neuron dysfunction. Moreover, in supplementary motor areas, there appears to be an increase in regional glucose metabolism as the neurologic condition deteriorates, possibly representing increased metabolic activity of the motor association cortex in response to primary loss of pyramidal cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1524517     DOI: 10.1001/archneur.1992.00530320077014

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  9 in total

Review 1.  Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.

Authors:  Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-08       Impact factor: 9.236

2.  Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis.

Authors:  Arianna Sala; Leonardo Iaccarino; Piercarlo Fania; Emilia G Vanoli; Federico Fallanca; Caterina Pagnini; Chiara Cerami; Andrea Calvo; Antonio Canosa; Marco Pagani; Adriano Chiò; Angelina Cistaro; Daniela Perani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-07       Impact factor: 9.236

Review 3.  Biomarkers in amyotrophic lateral sclerosis: facts and future horizons.

Authors:  Pierre-François Pradat; Michel Dib
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

4.  Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis.

Authors:  Marco Pagani; Johanna Öberg; Fabrizio De Carli; Andrea Calvo; Cristina Moglia; Antonio Canosa; Flavio Nobili; Silvia Morbelli; Piercarlo Fania; Angelina Cistaro; Adriano Chiò
Journal:  Hum Brain Mapp       Date:  2015-12-24       Impact factor: 5.038

Review 5.  Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.

Authors:  Federica Agosta; Daniele Altomare; Cristina Festari; Stefania Orini; Federica Gandolfo; Marina Boccardi; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Flavio Nobili; Zuzana Walker; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-01       Impact factor: 9.236

6.  Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis.

Authors:  Cecilia Marini; Silvia Morbelli; Angelina Cistaro; Cristina Campi; Claudia Caponnetto; Matteo Bauckneht; Alessandro Bellini; Ambra Buschiazzo; Iolanda Calamia; Mauro C Beltrametti; Simone Margotti; Piercarlo Fania; Ilaria Poggi; Corrado Cabona; Selene Capitanio; Roberta Piva; Andrea Calvo; Cristina Moglia; Antonio Canosa; AnnaMaria Massone; Flavio Nobili; Gianluigi Mancardi; Adriano Chiò; Michele Piana; Gianmario Sambuceti
Journal:  Brain       Date:  2018-08-01       Impact factor: 13.501

Review 7.  CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target?

Authors:  Tesfaye Wolde Tefera; Frederik J Steyn; Shyuan T Ngo; Karin Borges
Journal:  Cell Biosci       Date:  2021-01-11       Impact factor: 7.133

Review 8.  Lessons of ALS imaging: Pitfalls and future directions - A critical review.

Authors:  Peter Bede; Orla Hardiman
Journal:  Neuroimage Clin       Date:  2014-02-27       Impact factor: 4.881

Review 9.  Neuroimaging to investigate multisystem involvement and provide biomarkers in amyotrophic lateral sclerosis.

Authors:  Pierre-François Pradat; Mohamed-Mounir El Mendili
Journal:  Biomed Res Int       Date:  2014-04-17       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.